Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yasuaki Okuda. (2019) AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Modern Rheumatology 29:2, pages 268-274.
Read now
Read now
Alice Courties, Gilles Grateau, Peggy Philippe, René-Marc Flipo, Leonardo Astudillo, Bérengère Aubry-Rozier, Isabelle Fabreguet, Wafki Fahd, Olivier Fain, Pascal Guggenbuhl, Eric Hachulla, Thomas Papo, Christophe Richez, Jean Sibilia, Jacques Morel, Francis Berenbaum & Jérémie Sellam. (2015) AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid 22:2, pages 84-92.
Read now
Read now
Diego Real de Asúa, Ramón Costa, Jose María Galván, María Teresa Filigheddu, Davinia Trujillo & Julen Cadiñanos. (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clinical Epidemiology 6, pages 369-377.
Read now
Read now
M.D. Redondo-Pachón, R. Enríquez, A.E. Sirvent, E. Andrada, R. Noguera-Pons, I. Millán & F. Amorós. (2013) Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet’s Disease. Renal Failure 35:4, pages 547-550.
Read now
Read now
Articles from other publishers (18)
Sandra M. Ihne-Schubert, Malte Kircher, Rudolf A. Werner, Constantin Lapa, Hermann Einsele, Andreas Geier & Torben Schubert. (2023) Vector autoregression: Useful in rare diseases?—Predicting organ response patterns in a rare case of secondary AA amyloidosis. PLOS ONE 18:8, pages e0289921.
Crossref
Crossref
Jordan Thorne, David Clark, Laurette Geldenhuys, Keigan More, Amanda Vinson & Karthik Tennankore. (2022) Serum Amyloid A Protein–Associated Kidney Disease: Presentation, Diagnosis, and Management. Kidney Medicine 4:8, pages 100504.
Crossref
Crossref
Florian Garo, Juliette Chatelain, Cedric Aglae & Olivier Moranne. (2021) Two cases of secondary AA amyloidosis involving the skin and chronic kidney infection with a nephrotic syndrome in a high-income country. BMJ Case Reports 14:6, pages e239411.
Crossref
Crossref
D. Giannese, F. Ferro, D. Moriconi, A. G. Bonadio, E. Elefante, M. F. Egidi, A. Cupisti & C. Baldini. (2020) Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review. CEN Case Reports 10:1, pages 23-29.
Crossref
Crossref
D. G. Rumyantseva, E. M. Agafonova, S. O. Krasnenko, A. S. Starkova, M. M. Urumova & Sh. Erdes. (2020) Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis. Modern Rheumatology Journal 14:3, pages 45-49.
Crossref
Crossref
Shiang-Fen Huang, Ming-Han Chen, Fu-Der Wang, Chang-Youh Tsai, Chang-Phone Fung & Wei-Juin Su. (2018) Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders – A retrospective cohort study in Taiwan. Journal of Microbiology, Immunology and Infection 51:6, pages 784-793.
Crossref
Crossref
E. Baux, S. Henard, C. Alauzet, F. Goehringer, C. Laurain, J. Champigneulle, P. Vaillant, A. Hardy, C. Rabaud & T. May. (2015) Amylose AA secondaire à une tuberculose pulmonaire multi-résistante : implications thérapeutiques. Revue de Pneumologie Clinique 71:5, pages 297-300.
Crossref
Crossref
Tomoaki Murakami, Yasuo Inoshima & Naotaka Ishiguro. (2015) Systemic AA amyloidosis as a prion-like disorder. Virus Research 207, pages 76-81.
Crossref
Crossref
S. A. Jones, D. J. Fraser, C. A. Fielding & G. W. Jones. (2014) Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30:4, pages 564-574.
Crossref
Crossref
Julen Cadiñanos, Ramón Costa, Davinia Trujillo & Diego Real de Asúa. (2015) Amiloidosis sistémica secundaria AA. Medicina Clínica 144:7, pages 324-330.
Crossref
Crossref
Julen Cadiñanos, Ramón Costa, Davinia Trujillo & Diego Real de Asúa. (2015) Systemic secondary AA amyloidosis. Medicina Clínica (English Edition) 144:7, pages 324-330.
Crossref
Crossref
Kanata IBI, Tomoaki MURAKAMI, Wael Mohamed GODA, Naoki KOBAYASHI, Naotaka ISHIGURO & Tokuma YANAI. (2015) Prevalence of amyloid deposition in mature healthy chickens in the flock that previously had outbreaks of vaccine-associated amyloidosis. Journal of Veterinary Medical Science 77:10, pages 1241-1245.
Crossref
Crossref
Shunsuke Yamada, Akihiro Tsuchimoto, Yoshiki Kaizu, Masatomo Taniguchi, Kosuke Masutani, Hiroshi Tsukamoto, Hiroaki Ooboshi, Kazuhiko Tsuruya & Takanari Kitazono. (2014) Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis. CEN Case Reports 3:2, pages 237-243.
Crossref
Crossref
Graeme Jones & Changhai Ding. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
2023
2040
.
Masaru Matsui, Satoshi Okayama, Hideo Tsushima, Kenichi Samejima, Tomoko Kanki, Ayako Hasegawa, Katsuhiko Morimoto, Yasuhiro Akai, Masato Takano, Shiro Uemura, Chiho Ohbayashi & Yoshihiko Saito. (2014) Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis. Case Reports in Nephrology 2014, pages 1-6.
Crossref
Crossref
A. Cañas-Ventura, E. Rodríguez, M. Andreu & L. Márquez. (2013) Tocilizumab in Amyloidosis-Associated Kidney Disease Secondary to Inflammatory Bowel Diseases. Digestive Diseases and Sciences 58:9, pages 2736-2737.
Crossref
Crossref
Toshio Tanaka, Atsushi OgataMasashi Narazaki. (2013) Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Clinical Medicine Insights: Therapeutics 5, pages CMT.S9282.
Crossref
Crossref
Javier Rueda-Gotor, Miguel A González-Gay & Ricardo Blanco. (2012) Tocilizumab for the treatment of rheumatoid arthritis. Clinical Practice 9:3, pages 255-268.
Crossref
Crossref